Ardea Biosciences to Present Additional Data From Completed Phase 2b Combination Study of Lesinurad and Allopurinol

Ardea Biosciences, Inc. RDEA today announced that additional data from its completed Phase 2b study evaluating lesinurad in combination with allopurinol in gout patients not adequately responding to allopurinol alone will be presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism on May 26, 2011 in London, UK. The Company will also present additional data from a completed Phase 1b study evaluating the combination of lesinurad and febuxostat in gout patients, as well as data from a completed preclinical study of lesinurad's effect on hyperuricemia caused by the commonly used diuretic, hydrochlorothiazide. Lesinurad is Ardea's lead product candidate for the treatment of hyperuricemia and gout.